Venlafaxine ER

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
76
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Social Anxiety Disorder

Conditions

Social Anxiety Disorder

Trial Timeline

Dec 1, 1999 โ†’ Jun 1, 2003

About Venlafaxine ER

Venlafaxine ER is a phase 3 stage product being developed by Pfizer for Social Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00238719. Target conditions include Social Anxiety Disorder.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (6)

NCT IDPhaseStatus
NCT01485887Phase 3Completed
NCT00401726ApprovedCompleted
NCT00044772Phase 3Completed
NCT00038896Phase 3Completed
NCT00046020ApprovedCompleted
NCT00238719Phase 3Completed

Competing Products

20 competing products in Social Anxiety Disorder

See all competitors
ProductCompanyStageHype Score
LY686017 + paroxetine + placeboEli LillyPhase 2
52
atomoxetine + placeboEli LillyPhase 2/3
65
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Cariprazine + PlaceboAbbVieApproved
85
QuetiapineAstraZenecaApproved
85
quetiapineAstraZenecaPhase 3
77
quetiapineAstraZenecaPhase 2/3
65
Seroquel + Sugar PillAstraZenecaPhase 3
77
quetiapineAstraZenecaApproved
85
Pristiq + PlaceboPfizerApproved
84
Ziprasidone + SertralinePfizerPhase 2
51
Sertraline + PlaceboPfizerApproved
84
NefazodoneBristol Myers SquibbApproved
84
EscitalopramLundbeckApproved
82
Cipralex + PlaceboLundbeckPhase 2
49
BHV-0223 + PlaceboBiohavenPhase 2/3
60
VQW-765 + PlaceboVanda PharmaceuticalsPhase 3
69
PH94BVistagen TherapeuticsPhase 3
69
Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal SprayVistagen TherapeuticsPhase 2
44
PH94B Nasal Spray + Placebo Nasal SprayVistagen TherapeuticsPhase 3
69